Summary.-The hypothesis that there is prostaglandin-mediated hypercalcaemia associated with the Walker carcinosarcoma in the rat was tested by measuring PGE production during the development of the hypercalcaemia, and determining the effects of inhibition of prostaglandin synthesis on serum calcium concentration. Parathyroid hormone (PTH) activity was estimated by the determination of the serum concentration of immunoreactive PTH. There was a 3-fold increase in the urinary excretion of 7oa-hydroxy-5, 1 -diketotetranor -prostane -1,16-dioic acid (PGE-M), a major urinary metabolite of the E prostaglandins from basal levels. Treatment with indomethacin, a potent inhibitor of prostaglandin synthesis, did not lower serum calcium concentrations with two different doses (1-6 mg/kg/day orally and 5 mg/kg/day i.m.); effective inhibition of prostaglandin synthesis was demonstrated by the suppression of PGE-M excretion rates below basal levels. Serum concentrations of immunoreactive PTH were not significantly altered by either tumour growth or indomethacin. Dexamethasone (0 5 mg/kg/day i.m.) attenuated both the increased urinary excretion of PGE-M and the rise in serum calcium concentration, suggesting that one or several lipoxygenase products might be the actual mediators of the hypercalcaemia. We conclude that the hypercalcaemia in the rat with Walker carcinosarcoma is probably not mediated by E-prostaglandins and probably not by any other product of the cyclo-oxygenase pathway. The increased PGE turnover may be considered as a biochemical marker of tumour load, but not as an indicator of a prostaglandin-mediated hypercalcaemia.
C,ERTAIN types of hypercalcaemia in malignancy of both experimental animals and man may be mediated by prostaglandins (Tashjian, 1978; Seyberth et al., 1978; Seyberth, 1978) . The humoral mediator of the hypercalcaemia associated with the Walker carcinosarcoma in the rat has not been conclusively identified (Mundy, 1978) . This animal model is often used to study the pathogenesis of hypercalcaemia in breast cancer; the Walker carcinosarcoma was derived from a spontaneously developed tutmour of the rat mammary gland (Minne et al., 1975) . At least two candidates have been proposed as mediators of this type of hypercalcaemia: a parathyroid hormone (PTH)-like compound (Minne et al., 1975 (Minne et al., , 1978 and a prostaglandin, most likely PGE2 (Powles et al., 1973; Spiro & Mundy, 1979) .
We have investigated the hypothesis that hypercalcaemia in the Walker carcinosarcoma rat is prostaglandin-mediated. First, we assessed in vivo PGE2 production during tumour growth and the development of hypercalcaemia, and second, we blocked prostaglandin synthesis at the level of prostaglandin cyclo-H. WV. SEYBERTH ET AL.
oxygenase, and we tried to inhibit the release from phospholipids of arachidonate, the major substrate for prostaglandin synthesis. In some of these experiments immunoreactive PTH was determined during the pharmacological interventions.
Total PGE turnover in the rat was assessed by determining the excretion of a major urinary PGE-metabolite, 7a-hydroxy -5,11 -diketotetranorprostane -1, 16-dioic acid (Green, 1971;  Hamberg, 1972) and, as an index of renal PGE2 synthesis, the urinary output of PGE2 was also determined (Frolich et al., 1975) . Prostaglandin cyclooxygenase was inhibited by treatment with indomethacin (Flower, 1974) ; and dexamethasone was selected as an anti-inflammatory glucocorticoid which can prevent arachidonate release from phospholipids in cell culture and in isolated perfused organs (Tam et al., 1977; Lands, 1979) . Both kinds of pharmacological intervention have been used to demonstrate a prostaglandin-mediated hypercalcaemia associated with the HSDM1 fibrosarcoma in the mouse (Tashjian et al., 1977a) and with the VX2 carcinosarcoma in the rabbit (Seyberth et al., 1977; Tashjian et al., 1977b and creatinine.
In the first experiment, urine was collected the night before tumour transplantation and on the 6th and 8th days of tumour growth. Blood was also sampled on Days 6 and 8 for serum calcium, and on the 8th day only for PTH analysis; the animals were sacrificed. The test animals (n=7) were treated orally at 08.00 and 20.00 with 0-8 mg of indomethacin/kg body weight. The concurrent controls (n = 6) were handled in the same way except that they received no drug.
In the second experiment, animals were divided randomly into 3 groups (n = 8): controls, indomethacin treatment (5 mg/kg/ day, i.m.) and dexamethasone treatment (0 5 mg/kg/day, i.m.). Drugs were given at 08.00 and 20.00 beginning on the 5th day after tumour transplantation. These changes in the experimental design were necessary to prevent major side effects of indomethacin (e.g. intestinal ulceration and renal failure) and differences in tumour growth between the controls and dexamethasone-treated rats. At the end of this experiment indomethacin and dexamethasone serum levels were determined in the middle of the dosage interval. Ci/ mmol) were added to 5 ml of rat urine and the pH was adjusted to 3-2 with formic acid. The ethyl acetate extract was concentrated and chromatographed on a 2g open silica-gel column (lem i.d.) using the solvent system ethyl acetate: toluene (7: 3). PGE-M and PGE2 were eluted in 100 ml. After methylation with freshly prepared diazomethane, the material was subjected to high-performance liquid chromatography (HPLC) using a 10lm silica-gel column (Seyberth et al., 1976b) . Because no 2H-labelled PGE-M was present in the sample up to this preparative step, the radioactivity in the PGE-M peak of the HPLC chromatogram was determined, to assess the recovery of PGE-M. Subsequently eluates of PGE-M and PGE2 were converted to the methoxime and trimethylsilylether 456 PROSTAGLANDINS AND HYPERCALCAEMIA IN TUMOUR-BEARING RATS derivatives. After adding 1 Ig of d3-methoxime derivative of the methylester of PGE-M to the PGE-M sample, the isotope ratios were determined with a gas chromatographymass spectrometry (GC-MS) system. Miscellaneous procedures.-Serum PTH concentration was determined by radioimmunoassay according to the procedure of Streibl et al. (1979) . This method can detect serum PTH values in normal rats and can clearly discriminate between intact and parathyroidectomized rats (Minne et al., unpublished) . Serum concentrations of indomethacin were determined by the HPLC method of Skellern & Salole (1975) . Serum concentrations of dexamethasone were also determined by HPLC: serum (500 ,ul) was diluted 1:1 with water, poured on to 2 g of ExtrelutR (E. Merck, Darmstadt, W. Germany) and eluted with ethyl acetate (25 ml). Diazomethane was prepared as described previously (Sweetman et al., 1973) . Indomethacin and dexamethasone were gifts from Sharp and Dohme (Munich, W. Germany).
The aqueous indomethacin sodium salt solution was prepared by neutralization of indomethacin with sodium carbonate. Prednisolone was provided by E. Merck (Darmstadt, W. Germany).
HPLC of prostaglandins was performed with two Waters Associates (Milford, Mass., U.S.A.) pumps (Model 6000 A) coupled to a solvent-flow programmer (Model 660). The silica-gel column was a prepacked 10,um Porasil column (Waters Associates). For mass-spectrometric analysis a HewlettPackard HP 5992 A microprocessor-controlled GC-MS system (Hewlett-Packard Company, Palo Alto, Calif., U.S.A.) equipped with a glass capillary column (Erlenmaier et al., 1979) and working in the selected ionmonitoring mode was used.
Statistical methods.-Where appropriate, the results were subjected to an analysis of variance followed by analysis of co-variance and the Scheff6 test. Otherwise the rank-sign sum test was applied.
RESULTS
Five to 6 days after tumour transplantation, the Walker carcinosarcoma started to grow rapidly from an almost nonpalpable tumour to a tumour of 7.4 + 4-4 g (mean + s.d.) in the untreated rats and 6-4 + 1 7 g in the indomethacin-treated rats within 2 days. During that time hypercalcaemia was present in most rats and the urinary excretion of PGE-M rose about 3-fold (Fig. IA) . The animals with the highest PGE-M excretion rates were usually the ones with the highest serum calcium concentrations. However, the hypercalcaemia in the indomethacintreated rats was in the same range as in the control group, despite a significant decrease of PGE-M excretion below the basal level (Fig. IB) . Serum concentrations of immunoreactive PTH were 3*7 + 1-2 ,u S.U.I./100 ,A in the untreated rats and 3'4+1.0 ,u S.U.L./100 pl in the indomethacin-treated animals, which were not significantly different from those of untreated control rats (3.1 + 0-6 ,ul S.U.I./ 100 t1). PTH-mediated hypercalcaemia (Dent, 1962; Raisz et al., 1972 ) and a highly glucocorticoid -sensitive, OAF -induced hypercalcaemia (Mundy, 1978; Mundy et al., 1978) in addition to the intervention at a different level of prostaglandin synthesis. Although we have not measured OAF, it appears unlikely that this factor is the hypercalcaemic mediator, as intact prostaglandin synthesis is required for OAF production (Yoneda & Mundy, 1979) . The small lowering effect of dexamethasone on serum calcium does not argue against a PTH-mediated hypercalcaemia, because the dexamethasone serum concentrations in the rats are similar to those which have a direct inhibitory effect on bone-cell function in vitro (Raisz et al., 1972; Chen & Feldman, 1979) . In addition, serum concentrations of immunoreactive PTH in the upper normal range in the hypercalcaemic rats support the PTH hypothesis, particularly when the antiserum in the radioimmunoassay may cross-react only in part with ectopically secreted PTH. Serum concentrations of immunoreactive PTH were inappropriately high for a hypercalcaemic state, and previous experiments have shown that indomethacin does not influence PTH-induced hypercalcaemia (Seyberth et al., 1 976a) . However, for the final proof of a PTH-like compound as the mediator of the hypercalcaemia in the Walker tumour-bearing rat, studies with inhibitors of PTH production or with PTH antagonists will have to be performed. An alternative hypothesis to PTH-mediated hypercalcaemia is that the hypercalcaemia-inducing agent is a product synthesized via the lipoxygenase pathway of arachidonate metabolism; this pathway is not inhibited by indomethacin (Hamberg & Samuelsson, 1974 (Tam et al., 1977) . Therefore, there is apparently still sufficient non-esterified arachidonic acid available, to be metabolized by lipoxygenase to a variety of hydroxy polyunsaturated fatty acids (Borgeat & Samuelsson, 1979; Murphy et al., 1979 (Caro etal., 1979 
